ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARWR is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has supportive bullish moving averages and a recent run of favorable analyst target increases, but the current price of 79.07 is far above the latest Street target range shown, options sentiment is only mildly bullish, and there is no Intellectia AI Stock Picker or SwingMax buy signal today. My direct view: hold and wait for a better entry, rather than buying immediately at this level.
The trend is mixed-to-bullish. Price is above the key moving averages, with SMA_5 > SMA_20 > SMA_200, which supports an upward trend. However, MACD histogram is -0.192 and still below zero, showing momentum has softened. RSI_6 at 61.981 is neutral-to-slightly bullish, not overextended. The stock is sitting near resistance, with pivot 76.308, R1 81.037, and R2 83.959. At 79.07, ARWR is below first resistance but close enough that upside from here looks limited in the near term. The short-pattern estimate also points to modest weakness over the next month.
["Recent analyst upgrades and higher price targets, including Morgan Stanley\u2019s Overweight with $100 target and JPMorgan\u2019s Overweight with $88 target.", "Chardan raised its target to $90 after a positive fiscal Q2 report, citing a good start to the Redemplo launch.", "BofA increased its target to $93, reflecting a larger estimated market opportunity for Redemplo-sHTG.", "News on plozasiran showed encouraging clinical data in renal and hepatic impairment without dose adjustment, which supports the pipeline narrative.", "Sector backdrop remains constructive, with biotech broadly outperforming and M&A/IPO activity viewed positively by Bernstein."]
["Current Street target from Bernstein is only $46 with a Market Perform rating, showing not all analysts are bullish.", "MACD momentum is negative despite the uptrend in moving averages.", "The stock is trading near resistance, limiting immediate upside from current levels.", "No AI Stock Picker signal and no recent SwingMax signal.", "Similar-candlestick trend data suggests weak near-term performance over the next month.", "No meaningful insider, hedge fund, congress, or politician trading signal was identified."]
No usable financial snapshot was provided because the financial data returned an error. The latest quarter season mentioned in the analyst commentary is fiscal Q2, and the qualitative read from the news is that the Redemplo launch has started well. Based on the available data, the company appears to be in a growth-driven, catalyst-led phase rather than a mature earnings-proven phase, but I cannot assess revenue or earnings acceleration from the provided financials.
Analyst sentiment has trended more positive recently: BofA, Morgan Stanley, JPMorgan, Chardan, and Bernstein all updated views or targets in May-April 2026, with most targets raised into the $88-$100 range and multiple Buy/Overweight ratings. The main pro view is that ARWR has meaningful pipeline optionality and potential value unlock from the APOC3/sHTG opportunity and Redemplo launch. The con view is that one major house, Bernstein, still only rates it Market Perform with a much lower $46 target, indicating the Street is not fully aligned. Overall Wall Street pros are constructive, but not unanimous.
